Article
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2021
Yu Helena A, Paz-Ares Luis G, Yang James Chih-Hsin, Lee Ki Hyeong, Garrido Pilar, Park Keunchil, Kim Joo-Hang, Lee Dae Ho, Mao Huzhang, Wijayawardana Sameera R, Gao Ling, Hozak Rebecca R, Chao Bo H, Planchard David
Abstract excerpt
PURPOSE: We report the final analysis of JVDL (NCT02789345), which examined the combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2-directed antibody ramucirumab in patients with T790M-positive EGFR-mutant non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: This open-label, single-arm phase I study enrolled patients with EGFR T790M-positive NSCLC, who had progressed following...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.